Long-term outcomes for low-grade intracranial ganglioglioma: 30-Year experience from the Mayo Clinic

Julia J. Compton, Nadia N Laack, Laurence J. Eckel, David A. Schomas, Caterina Giannini, Fredric B. Meyer

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Object: Gangliogliomas comprise less than 1% of all brain tumors and occur most often in children. Therefore, there are a limited number of patients and data involving the use or role of adjuvant therapy after subtotal resections (STRs) of gangliogliomas. The objective of this study was to examine and review the Mayo Clinic experience of 88 patients with gangliogliomas, their follow-up, risk of recurrence, and the role of radiation therapy after STR or only biopsy. Methods: Eighty-eight patients with gangliogliomas diagnosed between 1970 and 2007 were reviewed. Data on clinical outcomes and therapy received were analyzed. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival. Results: The median age at diagnosis was 19 years. The median potential follow-up as of June 2008 was 142 months (range 9-416 months). Fifteen-year overall survival was 94%, median PFS was 5.6 years, with a 10-year PFS rate of 37%. Progressionfree survival was dramatically affected by extent of initial resection (p < 0.0001). Conclusions: This single-institution retrospective series of patients with gangliogliomas is unique given its large cohort size with a long follow-up duration, and confirms the excellent long-term survival rate in this group. The study also shows the importance of resection extent on likelihood of recurrence. Patients with gangliogliomas who undergo STR or biopsy alone have poor PFS. Radiation therapy may delay time to progression in patients with unresectable disease.

Original languageEnglish (US)
Pages (from-to)825-830
Number of pages6
JournalJournal of Neurosurgery
Volume117
Issue number5
DOIs
StatePublished - Nov 2012

Fingerprint

Ganglioglioma
Disease-Free Survival
Survival
Radiotherapy
Survival Rate
Biopsy
Recurrence
Brain Neoplasms
Therapeutics

Keywords

  • Ganglioglioma
  • Glioma
  • Low-grade glioma
  • Oncology
  • Pediatric
  • Progression-free survival
  • WHO Grade I tumor

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Long-term outcomes for low-grade intracranial ganglioglioma : 30-Year experience from the Mayo Clinic. / Compton, Julia J.; Laack, Nadia N; Eckel, Laurence J.; Schomas, David A.; Giannini, Caterina; Meyer, Fredric B.

In: Journal of Neurosurgery, Vol. 117, No. 5, 11.2012, p. 825-830.

Research output: Contribution to journalArticle

Compton, Julia J. ; Laack, Nadia N ; Eckel, Laurence J. ; Schomas, David A. ; Giannini, Caterina ; Meyer, Fredric B. / Long-term outcomes for low-grade intracranial ganglioglioma : 30-Year experience from the Mayo Clinic. In: Journal of Neurosurgery. 2012 ; Vol. 117, No. 5. pp. 825-830.
@article{0784355054134432a92b7d2ec365a67e,
title = "Long-term outcomes for low-grade intracranial ganglioglioma: 30-Year experience from the Mayo Clinic",
abstract = "Object: Gangliogliomas comprise less than 1{\%} of all brain tumors and occur most often in children. Therefore, there are a limited number of patients and data involving the use or role of adjuvant therapy after subtotal resections (STRs) of gangliogliomas. The objective of this study was to examine and review the Mayo Clinic experience of 88 patients with gangliogliomas, their follow-up, risk of recurrence, and the role of radiation therapy after STR or only biopsy. Methods: Eighty-eight patients with gangliogliomas diagnosed between 1970 and 2007 were reviewed. Data on clinical outcomes and therapy received were analyzed. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival. Results: The median age at diagnosis was 19 years. The median potential follow-up as of June 2008 was 142 months (range 9-416 months). Fifteen-year overall survival was 94{\%}, median PFS was 5.6 years, with a 10-year PFS rate of 37{\%}. Progressionfree survival was dramatically affected by extent of initial resection (p < 0.0001). Conclusions: This single-institution retrospective series of patients with gangliogliomas is unique given its large cohort size with a long follow-up duration, and confirms the excellent long-term survival rate in this group. The study also shows the importance of resection extent on likelihood of recurrence. Patients with gangliogliomas who undergo STR or biopsy alone have poor PFS. Radiation therapy may delay time to progression in patients with unresectable disease.",
keywords = "Ganglioglioma, Glioma, Low-grade glioma, Oncology, Pediatric, Progression-free survival, WHO Grade I tumor",
author = "Compton, {Julia J.} and Laack, {Nadia N} and Eckel, {Laurence J.} and Schomas, {David A.} and Caterina Giannini and Meyer, {Fredric B.}",
year = "2012",
month = "11",
doi = "10.3171/2012.7.JNS111260",
language = "English (US)",
volume = "117",
pages = "825--830",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "5",

}

TY - JOUR

T1 - Long-term outcomes for low-grade intracranial ganglioglioma

T2 - 30-Year experience from the Mayo Clinic

AU - Compton, Julia J.

AU - Laack, Nadia N

AU - Eckel, Laurence J.

AU - Schomas, David A.

AU - Giannini, Caterina

AU - Meyer, Fredric B.

PY - 2012/11

Y1 - 2012/11

N2 - Object: Gangliogliomas comprise less than 1% of all brain tumors and occur most often in children. Therefore, there are a limited number of patients and data involving the use or role of adjuvant therapy after subtotal resections (STRs) of gangliogliomas. The objective of this study was to examine and review the Mayo Clinic experience of 88 patients with gangliogliomas, their follow-up, risk of recurrence, and the role of radiation therapy after STR or only biopsy. Methods: Eighty-eight patients with gangliogliomas diagnosed between 1970 and 2007 were reviewed. Data on clinical outcomes and therapy received were analyzed. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival. Results: The median age at diagnosis was 19 years. The median potential follow-up as of June 2008 was 142 months (range 9-416 months). Fifteen-year overall survival was 94%, median PFS was 5.6 years, with a 10-year PFS rate of 37%. Progressionfree survival was dramatically affected by extent of initial resection (p < 0.0001). Conclusions: This single-institution retrospective series of patients with gangliogliomas is unique given its large cohort size with a long follow-up duration, and confirms the excellent long-term survival rate in this group. The study also shows the importance of resection extent on likelihood of recurrence. Patients with gangliogliomas who undergo STR or biopsy alone have poor PFS. Radiation therapy may delay time to progression in patients with unresectable disease.

AB - Object: Gangliogliomas comprise less than 1% of all brain tumors and occur most often in children. Therefore, there are a limited number of patients and data involving the use or role of adjuvant therapy after subtotal resections (STRs) of gangliogliomas. The objective of this study was to examine and review the Mayo Clinic experience of 88 patients with gangliogliomas, their follow-up, risk of recurrence, and the role of radiation therapy after STR or only biopsy. Methods: Eighty-eight patients with gangliogliomas diagnosed between 1970 and 2007 were reviewed. Data on clinical outcomes and therapy received were analyzed. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival. Results: The median age at diagnosis was 19 years. The median potential follow-up as of June 2008 was 142 months (range 9-416 months). Fifteen-year overall survival was 94%, median PFS was 5.6 years, with a 10-year PFS rate of 37%. Progressionfree survival was dramatically affected by extent of initial resection (p < 0.0001). Conclusions: This single-institution retrospective series of patients with gangliogliomas is unique given its large cohort size with a long follow-up duration, and confirms the excellent long-term survival rate in this group. The study also shows the importance of resection extent on likelihood of recurrence. Patients with gangliogliomas who undergo STR or biopsy alone have poor PFS. Radiation therapy may delay time to progression in patients with unresectable disease.

KW - Ganglioglioma

KW - Glioma

KW - Low-grade glioma

KW - Oncology

KW - Pediatric

KW - Progression-free survival

KW - WHO Grade I tumor

UR - http://www.scopus.com/inward/record.url?scp=84868356750&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868356750&partnerID=8YFLogxK

U2 - 10.3171/2012.7.JNS111260

DO - 10.3171/2012.7.JNS111260

M3 - Article

C2 - 22957524

AN - SCOPUS:84868356750

VL - 117

SP - 825

EP - 830

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 5

ER -